Different dose regimens of 5-fluorouracil and interferon-α in patients with metastatic colorectal carcinoma
- 31 December 1995
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (3) , 315-320
- https://doi.org/10.1016/0959-8049(94)00510-c
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Phase II trial of 5-fluorouracil and recombinant interferon alfa-2B in metastatic colorectal carcinomaEuropean Journal Of Cancer, 1992
- Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma assessment of activity and toxicityCancer, 1990
- Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.Journal of Clinical Oncology, 1990
- 5-Fluorouracil and Recombinant Alpha Interferon-2a in the Treatment of Advanced Colorectal Carcinoma: a Dose Optimization StudyJournal of Chemotherapy, 1990
- Interferon effects upon fluorouracil metabolism by HL-60 cellsBiochemical and Biophysical Research Communications, 1989
- A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.Journal of Clinical Oncology, 1989
- Continuous systemic 5‐fluorouracil infusion in advanced colorectal cancer: Results in 91 patientsJournal of Surgical Oncology, 1989
- Interferon inhibition of thymidine incorporation into DNA through effects on thymidine transport and uptakeJournal of Cellular Physiology, 1984
- Reporting results of cancer treatmentCancer, 1981
- Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory CompoundsNature, 1957